Viewing Study NCT02521051


Ignite Creation Date: 2025-12-24 @ 11:42 PM
Ignite Modification Date: 2025-12-31 @ 6:46 PM
Study NCT ID: NCT02521051
Status: TERMINATED
Last Update Posted: 2025-05-13
First Post: 2015-07-20
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
Sponsor: Massachusetts General Hospital
Organization: